Published in Neuropsychiatr Dis Treat on September 01, 2005
Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci (2008) 1.39
Genetics of early-onset obsessive-compulsive disorder. Eur Child Adolesc Psychiatry (2010) 0.97
Obsessive compulsive disorder as early manifestation of B12 deficiency. Indian J Psychol Med (2011) 0.89
Parental precaution: neurobiological means and adaptive ends. Neurosci Biobehav Rev (2010) 0.86
Neuroanatomical, neurochemical, and neurodevelopmental basis of obsessive-compulsive symptoms in schizophrenia. Indian J Psychol Med (2009) 0.85
Effects of gender and executive function on visuospatial working memory in adult obsessive-compulsive disorder. Eur Arch Psychiatry Clin Neurosci (2015) 0.81
Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study. BMC Psychiatry (2013) 0.80
The role of NMDA receptors in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology (Berl) (2010) 0.80
The role of the cholinergic system in the signal attenuation rat model of obsessive-compulsive disorder. Psychopharmacology (Berl) (2013) 0.77
Treatment of generalized anxiety disorder. Neuropsychiatr Dis Treat (2007) 0.77
Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD). Psychopharmacology (Berl) (2014) 0.76
Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior. Eur J Neurosci (2014) 0.75
Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci (2000) 18.84
Predictive reward signal of dopamine neurons. J Neurophysiol (1998) 15.02
Anterior cingulate conflict monitoring and adjustments in control. Science (2004) 12.50
Getting formal with dopamine and reward. Neuron (2002) 9.83
Contributions of anterior cingulate cortex to behaviour. Brain (1995) 9.43
Drug abuse: hedonic homeostatic dysregulation. Science (1997) 8.22
Relative reward preference in primate orbitofrontal cortex. Nature (1999) 7.57
Anterior prefrontal cortex: insights into function from anatomy and neuroimaging. Nat Rev Neurosci (2004) 5.39
Multiple reward signals in the brain. Nat Rev Neurosci (2000) 4.70
Dorsal anterior cingulate cortex: a role in reward-based decision making. Proc Natl Acad Sci U S A (2001) 4.20
Mesolimbocortical and nigrostriatal dopamine responses to salient non-reward events. Neuroscience (2000) 3.95
Anterior cingulate: single neuronal signals related to degree of reward expectancy. Science (2002) 3.91
Performance monitoring by the anterior cingulate cortex during saccade countermanding. Science (2003) 3.80
Cognitive inflexibility after prefrontal serotonin depletion. Science (2004) 3.44
Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behav Brain Res (2002) 3.40
Role for cingulate motor area cells in voluntary movement selection based on reward. Science (1998) 3.39
The spectrum of behaviors influenced by serotonin. Biol Psychiatry (1998) 2.98
The orbitofrontal cortex: neuronal activity in the behaving monkey. Exp Brain Res (1983) 2.80
Dopamine and the regulation of cognition and attention. Prog Neurobiol (2002) 2.72
A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry (2000) 2.48
Pathophysiological basis of vulnerability to drug abuse: role of an interaction between stress, glucocorticoids, and dopaminergic neurons. Annu Rev Pharmacol Toxicol (1996) 2.43
Prefrontal and cingulate unit activity during timing behavior in the monkey. Brain Res (1979) 2.41
Structure and function of dopamine receptors. Neurosci Biobehav Rev (2000) 2.40
The effects of tryptophan depletion on mood and psychiatric symptoms. J Affect Disord (2001) 2.28
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry (1996) 2.14
Influence of reward expectation on behavior-related neuronal activity in primate striatum. J Neurophysiol (1998) 2.11
Contributions of the prefrontal cortex to the neural basis of human decision making. Neurosci Biobehav Rev (2002) 2.00
Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl (1998) 1.92
Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry (1996) 1.85
Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science (1999) 1.85
Reward-related neuronal activity during go-nogo task performance in primate orbitofrontal cortex. J Neurophysiol (2000) 1.74
Modifications of reward expectation-related neuronal activity during learning in primate striatum. J Neurophysiol (1998) 1.68
Protein kinase C activation regulates human serotonin transporters in HEK-293 cells via altered cell surface expression. J Neurosci (1997) 1.63
Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. Brain Res Brain Res Rev (1997) 1.61
Influence of expectation of different rewards on behavior-related neuronal activity in the striatum. J Neurophysiol (2001) 1.58
Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch Gen Psychiatry (1990) 1.56
Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry (1994) 1.56
Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry (1987) 1.56
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry (1995) 1.52
5-HT system and cognition. Neurosci Biobehav Rev (1999) 1.49
Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord (1998) 1.47
A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry (1993) 1.44
Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol (2004) 1.40
Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry (1996) 1.37
Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem (1998) 1.34
Modifications of reward expectation-related neuronal activity during learning in primate orbitofrontal cortex. J Neurophysiol (2000) 1.33
The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals. Neuroscience (1994) 1.24
Regulated phosphorylation and trafficking of antidepressant-sensitive serotonin transporter proteins. Biol Psychiatry (1998) 1.22
Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. J Clin Psychiatry (1998) 1.16
A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry (1999) 1.14
Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry (2004) 1.12
Obsessive-compulsive disorder and serotonin: is there a connection? Biol Psychiatry (1985) 1.05
Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology (1995) 1.05
Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry (2003) 1.04
Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry (1992) 1.01
Stepping out of the box: information processing in the neural networks of the basal ganglia. Curr Opin Neurobiol (2001) 1.00
Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry (1999) 1.00
Single cell activity in ventral prefrontal cortex of behaving monkeys. Brain Res (1981) 0.99
Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry (1987) 0.99
Comparison of neuronal activity in the rostral supplementary and cingulate motor areas during a task with cognitive and motor demands. Eur J Neurosci (2002) 0.98
Serotonin transporters in obsessive-compulsive disorder: a positron emission tomography study with [(11)C]McN 5652. Biol Psychiatry (2003) 0.96
The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. J Clin Psychiatry (1992) 0.95
Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry (1987) 0.93
5HT1Dbeta Receptor gene implicated in the pathogenesis of Obsessive-Compulsive Disorder: further evidence from a family-based association study. Mol Psychiatry (2002) 0.93
Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Arch Gen Psychiatry (1988) 0.93
Functional significance of mesolimbic dopamine. Neurosci Biobehav Rev (1995) 0.92
Clomipramine treatment of obsessive-compulsive disorder. II. Biochemical aspects. Arch Gen Psychiatry (1980) 0.91
Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry (1988) 0.90
Neuroanatomical aspects of cognitive-behavioural therapy response in obsessive-compulsive disorder. An evolving perspective on brain and behaviour. Br J Psychiatry Suppl (1998) 0.89
Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology (1995) 0.89
1-(m-chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biol Psychiatry (1989) 0.88
Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch Gen Psychiatry (1994) 0.88
Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry (2000) 0.88
Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res (1991) 0.86
Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry (1992) 0.86
Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. Prog Neuropsychopharmacol Biol Psychiatry (1999) 0.86
Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Res (1992) 0.86
Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Biol Psychiatry (1991) 0.85
Decreased platelet 3H-paroxetine binding in obsessive-compulsive patients. Neuropsychobiology (1996) 0.85
Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharmacol (1981) 0.85
Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry (2000) 0.85
Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Arch Gen Psychiatry (1994) 0.84
Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder. Eur J Nucl Med Mol Imaging (2003) 0.84
Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biol Psychiatry (1999) 0.84
Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder. Biol Psychiatry (1991) 0.84
Tryptophan depletion in obsessive-compulsive patients. Biol Psychiatry (1996) 0.83
Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. Psychopharmacology (Berl) (2000) 0.83
Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol (2001) 0.83
Recent findings in the genetics of OCD. J Clin Psychiatry (2002) 0.82
Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry (1996) 0.82
m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry (1995) 0.81
Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. Arch Gen Psychiatry (1989) 0.81
Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin Pharmacol Ther (1977) 0.81
Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder. Psychopharmacology (Berl) (1998) 0.80
A family-based association study of the 5-HT-1Dbeta receptor gene in obsessive-compulsive disorder. Int J Neuropsychopharmacol (2004) 0.80
Whole blood serotonin in juvenile obsessive-compulsive disorder. Biol Psychiatry (1991) 0.80
Cortisol response to d-fenfluramine in patients with obsessive-compulsive disorder and in healthy subjects: evidence for a gender-related effect. Neuropsychobiology (1997) 0.80
Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology (Berl) (1986) 0.79
Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder. Biol Psychiatry (2001) 0.79
Altered cAMP-dependent protein kinase A in platelets of patients with obsessive-compulsive disorder. Am J Psychiatry (2000) 0.79
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med (2008) 3.52
Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. Brain (2005) 2.19
Statistical determination of the optimal subthalamic nucleus stimulation site in patients with Parkinson disease. J Neurosurg (2007) 2.18
Risk factors for the occurrence of electroencephalogram abnormalities during induction of anesthesia with sevoflurane in nonepileptic patients. Anesthesiology (2007) 2.10
Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg (2004) 2.09
The effects of coffee and napping on nighttime highway driving: a randomized trial. Ann Intern Med (2006) 2.04
French field experience with buprenorphine. Am J Addict (2004) 1.96
Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol (2009) 1.87
Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model. Exp Neurol (2009) 1.70
Lack of agreement between direct magnetic resonance imaging and statistical determination of a subthalamic target: the role of electrophysiological guidance. J Neurosurg (2002) 1.68
Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol (2012) 1.61
Fatigue, sleep restriction and driving performance. Accid Anal Prev (2005) 1.60
High-frequency stimulation in Parkinson's disease: more or less? Trends Neurosci (2005) 1.59
Neuronal correlates of obsessions in the caudate nucleus. Biol Psychiatry (2007) 1.58
Meta-analysis of brain volume changes in obsessive-compulsive disorder. Biol Psychiatry (2008) 1.55
Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res (2002) 1.53
Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance. Sleep Med (2005) 1.50
Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson's disease. Br J Nutr (2005) 1.47
Validation of Horne and Ostberg morningness-eveningness questionnaire in a middle-aged population of French workers. J Biol Rhythms (2004) 1.47
Deep brain stimulation for Parkinson's disease: potential risk of tissue damage associated with external stimulation. Ann Neurol (2004) 1.42
Pathophysiology of obsessive-compulsive disorder: a necessary link between phenomenology, neuropsychology, imagery and physiology. Prog Neurobiol (2004) 1.40
Latest view on the mechanism of action of deep brain stimulation. Mov Disord (2008) 1.39
Provocation of obsessive-compulsive symptoms: a quantitative voxel-based meta-analysis of functional neuroimaging studies. J Psychiatry Neurosci (2008) 1.39
Sleep disorders and accidental risk in a large group of regular registered highway drivers. Sleep Med (2010) 1.31
Dual effect of high-frequency stimulation on subthalamic neuron activity. J Neurosci (2003) 1.30
Thalamic neuronal activity in dopamine-depleted primates: evidence for a loss of functional segregation within basal ganglia circuits. J Neurosci (2005) 1.30
Effects of sleep deprivation on Color-Word, Emotional, and Specific Stroop interference and on self-reported anxiety. Brain Cogn (2005) 1.30
The circadian and homeostatic modulation of sleep pressure during wakefulness differs between morning and evening chronotypes. J Sleep Res (2003) 1.29
Late emergence of synchronized oscillatory activity in the pallidum during progressive Parkinsonism. Eur J Neurosci (2007) 1.27
Shaping of motor responses by incentive values through the basal ganglia. J Neurosci (2007) 1.24
The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin (2003) 1.20
Age, performance and sleep deprivation. J Sleep Res (2004) 1.17
From single extracellular unit recording in experimental and human Parkinsonism to the development of a functional concept of the role played by the basal ganglia in motor control. Prog Neurobiol (2002) 1.17
Dynamic changes in the cortex-basal ganglia network after dopamine depletion in the rat. J Neurophysiol (2008) 1.15
Fatigue, sleepiness, and performance in simulated versus real driving conditions. Sleep (2005) 1.14
Gray matter alterations in obsessive-compulsive disorder: an anatomic likelihood estimation meta-analysis. Neuropsychopharmacology (2009) 1.12
Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis (2010) 1.11
Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord (2004) 1.08
D5 (not D1) dopamine receptors potentiate burst-firing in neurons of the subthalamic nucleus by modulating an L-type calcium conductance. J Neurosci (2003) 1.06
Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease. Neurobiol Dis (2010) 1.02
Aging and nocturnal driving: better with coffee or a nap? A randomized study. Sleep (2007) 1.00
PRRT2 mutations: a major cause of paroxysmal kinesigenic dyskinesia in the European population. Neurology (2012) 0.99
Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis (2006) 0.99
Impact of high-frequency stimulation parameters on the pattern of discharge of subthalamic neurons. J Neurophysiol (2005) 0.99
Fatigue, sleep restriction, and performance in automobile drivers: a controlled study in a natural environment. Sleep (2003) 0.99
Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry (2007) 0.99
Acute versus chronic partial sleep deprivation in middle-aged people: differential effect on performance and sleepiness. Sleep (2012) 0.98
Deep brain stimulation for OCD and major depression. Am J Psychiatry (2005) 0.98
Sleepiness, near-misses and driving accidents among a representative population of French drivers. J Sleep Res (2010) 0.95
Maintenance of wakefulness test as a predictor of driving performance in patients with untreated obstructive sleep apnea. Sleep (2007) 0.95
Screening of the THAP1 gene in patients with early-onset dystonia: myoclonic jerks are part of the dystonia 6 phenotype. Neurogenetics (2010) 0.94
High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci (2010) 0.94
A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Mov Disord (2007) 0.94
Sharp and sleepy: evidence for dissociation between sleep pressure and nocturnal performance. J Sleep Res (2008) 0.94
Maintenance of Wakefulness Test, obstructive sleep apnea syndrome, and driving risk. Ann Neurol (2008) 0.93
Sleep duration and caffeine consumption in a French middle-aged working population. Sleep Med (2005) 0.92
Delayed kindling epileptogenesis and increased neurogenesis in adult rats housed in an enriched environment. Brain Res (2002) 0.91
Anatomical alterations and symptom-related functional activity in obsessive-compulsive disorder are correlated in the lateral orbitofrontal cortex. Biol Psychiatry (2009) 0.91
Extended driving impairs nocturnal driving performances. PLoS One (2008) 0.91